Shares of Ocular Therapeutix Inc. rose Thursday after the Bedford biotechnology company said it had struck a deal with Regeneron Pharmaceuticals Inc. to jointly develop a sustained-release treatment for wet age-related macular degeneration, a vision-threatening eye disease. Under the collaboration, Regeneron, based in Tarrytown, N.Y., has the option to exclusively license Ocular's hydrogel-based drug delivery system.
http://ift.tt/2dPOb0e
No comments:
Post a Comment